Search

Request for Quote (RFQ): If you'd like us to help you source a Quotation for any particular products or from any suppliers, please click here. Once submitted, we will try and place you in contact with a suitable supplier within 48 hours.

Search is Loading...

Results 1 - 10 of 129 for RNAi.

Next>

Targeted Nanoparticles as a Safe Platform for Delivery of RNAi Payloads to Immune Cells

RNA interference (RNAi) is a powerful strategy for suppressing gene expression in a sequence-specific manner. This strategy offers new potential opportunities for treating various diseases by...

http://www.azonano.com/article.aspx?ArticleID=2387 | 16 Sep 2009
Abrasion Resistant Coatings Using Nanomaterials Like NanoDur Alumina From Nanophase

The incorporation of nanomaterials in surface coatings can provide long-term abrasion resistance without significantly effecting optical clarity, gloss, color or physical properties. NanoDur alumina...

http://www.azonano.com/article.aspx?ArticleID=1642 | 18 Jul 2006
Report Examines the Fundamentals of RNAi's Technologies, Markets and Companies

Research and Markets has announced the addition of Jain PharmaBiotech's new report "RNAi - Technologies, Markets and Companies" to their offering. RNA interference (RNAi) or gene silencing...

http://www.azonano.com/news.aspx?newsID=9841 | 10 Feb 2009
Researchers Gain Access to Sigma-Aldrich's Leading MISSION shRNA Libraries

Sigma-Aldrich, a leading life science company and member of The RNAi Consortium (TRC), proudly welcomes the Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program. The...

http://www.azonano.com/news.aspx?newsID=8137 | 15 Oct 2008
Five Research Projects to Receive Total of More Than $400,000 in RNAi Screening Tools

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has established a grant program to award life science researchers more than $400,000...

http://www.azonano.com/news.aspx?newsID=13124 | 13 Aug 2009
RNA Interference Company to Present at Discovery on Target Conference

Dicerna Pharmaceuticals, Inc., an RNA interference company developing novel therapeutics in multiple disease areas, today announced that Bob D. Brown, Ph.D., senior vice president of...

http://www.azonano.com/news.aspx?newsID=8260 | 22 Oct 2008
RXi Pharmaceuticals CSO Presents Pre-Clinical Data on Novel RNAi Therapeutic Approaches at IBC's TIDES Conference

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi),...

http://www.azonano.com/news.aspx?newsID=11627 | 21 May 2009
Bioo Scientific Receives SBIR Phase II Award from NSF to Develop a Targeted in Vivo RNAi Delivery Technology

Bioo Scientific, an Austin, TX based biotechnology company, announced today that it has been awarded a $500,000 Small Business Innovation Research (SBIR) Phase II grant from the National...

http://www.azonano.com/news.aspx?newsID=12883 | 30 Jul 2009
Alnylam Issued Patent for RNAi Therapeutics

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of intent to grant for a...

http://www.azonano.com/news.aspx?newsID=11001 | 20 Apr 2009
Alnylam, Cenix and IMM Discover New Targets in Malaria Infection with RNAi Technology

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Cenix BioScience GmbH, a leading RNAi-focused contract research organization, today announced the...

http://www.azonano.com/news.aspx?newsID=8617 | 12 Nov 2008

Result Page 12 3 4 5 6 7 8 9 10 Next